Target intelligence / Profile preview

Nitrogenous metabolic wastes (Gut microbial metabolism)

Molecular classification
Metabolite, Metabolic pathway
01

Overview

Nitrogenous metabolic wastes, including urea, ammonia, and creatinine, are byproducts of protein metabolism that are typically cleared by the kidneys. In conditions like chronic kidney disease (CKD) or liver failure, these wastes accumulate and translocate into the gastrointestinal tract, where they interact with the gut microbiota (Ramezani & Raj, 2014). Gut microbial metabolism of these wastes involves enzymes like urease, which converts urea into ammonia, and other pathways that produce toxic metabolites like indoxyl sulfate and p-cresyl sulfate (Vaziri et al., 2013). This target represents a therapeutic focus where the gut is used as a surrogate kidney or bioreactor to remove nitrogenous burdens. Pharmacological interventions include oral adsorbents like AST-120, which bind toxin precursors, and probiotics or engineered bacteria like SYNB1020 that sequester or degrade nitrogenous compounds (Schulman et al., 2006; Kurtz et al., 2019). By modulating this microbial metabolism, clinicians aim to reduce systemic uremic toxicity and slow the progression of renal or hepatic complications.

Other names
Uremic toxinsNitrogenous solutesGut-derived uremic toxinsMicrobial nitrogen metabolismEnterohepatic nitrogen cycle
02

Mechanism of action

Therapeutic strategies involve the adsorption of nitrogenous precursors (e.g., indole) by oral sorbents, the sequestration of ammonia by engineered bacteria, or the enzymatic degradation of urea and other wastes by probiotic consortia to reduce systemic toxin levels (Vaziri et al., 2013; Kurtz et al., 2019).

03

Biological functions

Nitrogen metabolismProtein catabolismEnterohepatic circulation of ureaBacterial fermentation
04

Disease associations

Chronic kidney diseaseHepatic encephalopathyHyperammonemiaEnd-stage renal diseaseUremia
05

Safety considerations

Gastrointestinal side effects (constipation, bloating)Potential for gut microbiome dysbiosisRisk of systemic absorption of bacterial metabolites in patients with compromised gut barriers
06

Interacting drugs

AST-120 (Kremezin)

5 more in the full profile.

07

Biomarkers

Blood urea nitrogen (BUN)Serum creatinineSerum ammoniaIndoxyl sulfatep-Cresyl sulfateTrimethylamine N-oxide (TMAO)

Beyond the preview

Go deeper on Nitrogenous metabolic wastes (Gut microbial metabolism).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nitrogenous metabolic wastes (Gut microbial metabolism).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call